An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Moleculin Biotech (NASDAQ:MBRX) CEO, Walter Klemp, discusses the positive interim data from the ongoing clinical trial on Annamycin for Acute Myeloid Leukemia (AML) treatment in a Virtual Investor 'What This Means' segment hosted by JTC Team. The segment highlights Annamycin's differentiation in the current AML treatment landscape and the investment opportunity for Moleculin.
Walter Klemp, CEO di Moleculin Biotech (NASDAQ:MBRX), discute i dati intermedi positivi del trial clinico in corso su Annamycin per il trattamento della Leucemia Mieloide Acuta (AML) in un segmento 'Cosa significa questo' per investitori virtuali, ospitato dal Team JTC. Il segmento evidenzia come Annamycin si differenzi nel panorama attuale dei trattamenti per AML e l'opportunità di investimento per Moleculin.
El CEO de Moleculin Biotech (NASDAQ:MBRX), Walter Klemp, discute los datos interinos positivos del ensayo clínico en curso sobre Annamycin para el tratamiento de la Leucemia Mieloide Aguda (AML) en un segmento para inversores virtuales llamado 'Qué significa esto', presentado por el equipo de JTC. Este segmento destaca la diferenciación de Annamycin en el panorama actual del tratamiento del AML y la oportunidad de inversión para Moleculin.
몰레큘린 바이오텍(Moleculin Biotech, 나스닥:MBRX)의 CEO 월터 클렘프는 JTC 팀이 주최하는 가상 투자자 '이것이 의미하는 바' 세그먼트에서 급성 골수성 백혈병(AML) 치료를 위한 아남마이신의 진행 중인 임상 시험의 긍정적인 중간 데이터에 대해 논의합니다. 이 세그먼트는 현재의 AML 치료 환경에서 아남마이신의 차별화와 몰레큘린에 대한 투자 기회를 강조합니다.
Walter Klemp, PDG de Moleculin Biotech (NASDAQ:MBRX), discute les données intermédiaires positives de l'essai clinique en cours sur Annamycin pour le traitement de la Leucémie Myéloïde Aiguë (AML) lors d'un segment pour investisseurs virtuels intitulé 'Ce que cela signifie', organisé par l'équipe JTC. Le segment met en lumière la différenciation d'Annamycin dans le paysage actuel du traitement de l'AML et l'opportunité d'investissement pour Moleculin.
Walter Klemp, CEO von Moleculin Biotech (NASDAQ:MBRX), erörtert die positiven Zwischendaten aus der laufenden klinischen Studie zu Annamycin für die Behandlung von Akuter Myeloischer Leukämie (AML) in einem virtuellen Investorensegment 'Was das bedeutet', das vom JTC Team veranstaltet wird. Das Segment hebt die Differenzierung von Annamycin in der aktuellen AML-Behandlungslandschaft und die Investitionsmöglichkeit für Moleculin hervor.
Positive
None.
Negative
None.
Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity
FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech (NASDAQ:MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses.
As part of this "What This Means" segment, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, discusses highlights from the Company's recently announced positive interim data from its ongoing clinical trial evaluating Annamycin for the treatment of subjects with Acute Myeloid Leukemia (AML), how Annamycin is differentiated in the current treatment landscape, and the Moleculin investment opportunity.
The Virtual Investor "What This Means" segment featuring Moleculin Biotech is now available here. Additional videos from the "What This Means" series are available on demand at www.virtualinvestorco.com.
About JTC Team
JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.
Contact:
Jenene Thomas JTC Team, LLC T: +1 (833) 475-8247 jtc@jtcir.com
What is the focus of the Virtual Investor 'What This Means' segment hosted by JTC Team featuring Moleculin Biotech (MBRX)?
The segment focuses on discussing the positive interim data from the ongoing clinical trial on Annamycin for the treatment of Acute Myeloid Leukemia (AML) and highlighting Annamycin's differentiation in the current AML treatment landscape.
Who is the CEO of Moleculin Biotech (MBRX) mentioned in the press release?
The CEO of Moleculin Biotech mentioned in the press release is Walter Klemp.
What is the main topic of discussion by Walter Klemp in the 'What This Means' segment?
Walter Klemp discusses the positive interim data from the ongoing clinical trial on Annamycin for the treatment of Acute Myeloid Leukemia (AML) and highlights Annamycin's differentiation in the current treatment landscape.
Where can additional videos from the 'What This Means' series be found?
Additional videos from the 'What This Means' series can be found on demand at www.virtualinvestorco.com.
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.
